Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
View Patent ↗Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.
1. A compound of the Formula (I):
wherein:
X is phenyl;
Y is 2-pyridyl;
A is C 0 alkyl,
B is C 0 alkyl,
X is optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups;
A is C 0 alkyl, B is —C 0 alkyl,
Y is optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 5 , —NR 5 R 6 , —C(═NR 5 )NR 6 R 7 , —N(═NR 5 )NR 6 R 7 , —NR 5 COR 6 , —NR 5 CO 2 R 6 , —NR 5 SO 2 R 8 , —NR 5 CONR 6 R 7 , —SR 8 , —SOR 8 , —SO 2 R 8 , —SO 2 NR 5 R 6 , —COR 5 , —CO 2 R 5 , —CONR 5 R 6 , —C(═NR 5 )R 6 , or —C(═NOR 5 )R 6 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups;
W is —C 3-7 cycloalkyl, -heteroC 3-7 cycloalkyl, —C 0-6 alkylaryl, or —C 0-6 alkylheteroaryl optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents;
Z is —C 3-7 cycloalkyl, -heteroC 3-7 cycloalkyl, —C 0-6 alkylaryl, or —C 0-6 alkylheteroaryl optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1, —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents;
one of W and Z is optionally absent;
R 1 , R 2 , and R 3 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;
R 4 is —C 1-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl),—N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;
R 5 , R 6 , and R 7 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;
R 8 is —C 1-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents;
R 9 and R 10 each independently is —C 0-6 alkyl, —C 3-7 cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), —N(C 0-6 alkyl)(aryl) substituents; and
any N may be an N-oxide;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 wherein:
X is phenyl, which is optionally substituted with 1-5 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.
3. The compound according to claim 1 wherein:
Y is 2-pyridyl, which is optionally substituted with 1-4 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1 alkenyl, —C 1-6 alkynyl, —OR 5 , —NR 5 R 6 , —C(═NR 5 )NR 6 R 7 , —N(═NR 5 )NR 6 R 7 , —NR 5 COR 6 , —NR 5 CO 2 R 6 , —NR 5 SO 2 R 8 , —NR 5 CONR 6 R 7 , —SR 8 , —SOR 8 , —SO 2 R 8 , —SO 2 NR 5 R 6 , —COR 5 , —CO 2 R 5 , —CONR 5 R 6 , —C(═NR 5 )R 6 , or —C(═NOR 5 )R 6 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the —C 1-6 alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C 1-6 alkyl, —O(C 0-6 alkyl), —O(C 3-7 cycloalkyl), —O(aryl), —N(C 0-6 alkyl)(C 0-6 alkyl), —N(C 0-6 alkyl)(C 3-7 cycloalkyl), or —N(C 0-6 alkyl)(aryl) groups.
4. The compound according to claim 1 wherein:
W is —C 0-6 alkylaryl, or —C 0-6 alkylheteroaryl optionally substituted with 1-7 independent halogen, —CN, NO 2 , —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —OR 1 , —NR 1 R 2 , —C(═NR 1 )NR 2 R 3 , —N(═NR 1 )NR 2 R 3 , —NR 1 COR 2 , —NR 1 CO 2 R 2 , —NR 1 SO 2 R 4 , —NR 1 CONR 2 R 3 , —SR 4 , —SOR 4 , —SO 2 R 4 , —SO 2 NR 1 R 2 , —COR 1 , —CO 2 R 1 , —CONR 1 R 2 , —C(═NR 1 )R 2 , or —C(═NOR 1 )R 2 substituents.
5. A compound which is selected from the group consisting of:
1-methyl-3-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]imidazolidin-2-one;
2-[2-(4-pyridin-2-ylphenyl)-2H-tetrazol-5-yl]pyridine;
2-[2-(4-pyridin-4-ylphenyl)-2H-tetrazol-5-yl]pyridine;
2-{2-[3-(1H-imidazol-1-yl)phenyl]-2H-tetrazol-5-yl}pyridine;
2-[2-(2-pyrazin-3-ylphenyl)-2H-tetrazol-5-yl]pyridine;
2-[2-(4-morpholin-3-ylphenyl)-2H-tetrazol-5-yl]pyridine;
2-{2-[3-(2H-tetrazol-5-yl)phenyl]-2H-tetrazol--yl}pyridine; and
2-pyridin-2-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile;
or a pharmaceutically acceptable salt thereof.
6. A compound which selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. A pharmaceutical composition comprising the compound of claim 5 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising the compound of claim 6 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.